Back to previous section

Oxford Nanopore warns of 'material uncertainty and risk' in US

Biotechnology company Oxford Nanopore warned of "material uncertainty and risk" surrounding its US business on Tuesday after Donald Trump vowed to cut federal government spending by up to $1.0trn per year.

  • Oxford Nanopore Technologies
  • 04 March 2025 09:59:03
Oxford Nanopore Technologies

Source: Sharecast

Funding to the US National Institutes of Health was at risk, said Oxford Nanopore, which has as much as 16% of its revenues exposed to funding from NIH and other US federal institutions. It also said a "tightening of export control restrictions" would likely weigh on its underlying performance.

The FTSE 250-listed group expects future growth "to be somewhat impacted by changes to Federal funding in the US for institutions such as the NIH". However, it noted that "the materiality of this impact" was still uncertain as the situation was still evolving.

On another note, Oxford Nanopore posted an 11.1% jump in revenues to £183.2m in FY24, with gross profits up 16.5% at £105.4m and gross margins improving 420 basis points to 57.5%. Adjusted underlying losses, however, widened 11.2% to £116.1m.

As of 0955 GMT, Oxford Nanopore shares were down 6.57% at 98.20p.

Reporting by Iain Gilbert at Sharecast.com

FTSE 250 ( MCX )

Isin: N/A
Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change: 19.30 ( 0.08 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Lloyds and Lloyds Bank are trading names of Halifax Share Dealing Limited. The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2026 Refinitiv, an LSEG business. All rights reserved.